Copyrighted Material
Total Page：16
File Type：pdf, Size：1020Kb
Index Note: page numbers in italics refer to figures; those in bold to tables or boxes. abacavir 686 tolerability 536–537 children and adolescents 461 acamprosate vascular dementia 549 haematological 798, 805–807 alcohol dependence 397, 397, 402–403 see also donepezil; galantamine; hepatic impairment 636 eating disorders 669 rivastigmine HIV infection 680 re‐starting after non‐adherence 795 acetylcysteine (N‐acetylcysteine) learning disability 700 ACE inhibitors see angiotensin‐converting autism spectrum disorders 505 medication adherence and 788, 790 enzyme inhibitors obsessive compulsive disorder 364 Naranjo probability scale 811, 812 acetaldehyde 753 refractory schizophrenia 163 older people 525 acetaminophen, in dementia 564, 571 acetyl‐L‐carnitine 159 psychiatric see psychiatric adverse effects acetylcholinesterase (AChE) 529 activated partial thromboplastin time 805 renal impairment 647 acetylcholinesterase (AChE) acute intoxication see intoxication, acute see also teratogenicity inhibitors 529–543, 530–531 acute kidney injury 647 affective disorders adverse effects 537–538, 539 acutely disturbed behaviour 54–64 caffeine consumption 762 Alzheimer’s disease 529–543, 544, 576 intoxication with street drugs 56, 450 non‐psychotropics causing 808, atrial fibrillation 720 rapid tranquillisation 54–59 809, 810 clinical guidelines 544, 551, 551 acute mania see mania, acute stupor 107, 108, 109 combination therapy 536 addictions 385–457 see also bipolar disorder; depression; delirium 675 S‐adenosyl‐l‐methionine 275 mania dosing 535 ADHD see attention deficit hyperactivity ageing drug interactions 223, 539–540, disorder pharmacodynamic changes 525 541–542 adherence, medication 787–793 pharmacokinetic changes 526 efficacy 532–533, 534 assessment 732, 789 see also older people Lewy body dementia 538, 550, 576, 717 children and adolescents 486 aggressive behaviour mechanism of action 529 enhancing 789–792 autism spectrum disorders 506–508 mild cognitive impairment 533, factors affecting 788 benzodiazepine‐associated 374, 381–383 537, 550 lithium therapy 206, 209 carbamazepine 222 myasthenia gravis 564, 567 rates 787–789 dementia see behavioural and non‐cognitive symptoms of re‐starting medication after missed psychological symptoms (BPSD) of dementia 535, 576 COPYRIGHTEDdoses 794–797, 795 MATERIALdementia other dementias 550–551 schizophrenia 4, 27, 42, 787–788, 790 Huntington’s disease 706 Parkinson’s disease 550, 716, 717 adolescents see children and adolescents learning disabilities 701–702 renal impairment 656 adverse drug reactions (ADR) lithium 207 re‐starting after non‐adherence 795 autism spectrum disorder 504 non‐psychotropics causing 809 stopping treatment 540–543 biochemical 798, 799–804 valproate 215 switching between 534 breastfed infants 620, 622–630 see also acutely disturbed behaviour The Maudsley Prescribing Guidelines in Psychiatry, Thirteenth Edition. David M. Taylor, Thomas R. E. Barnes and Allan H. Young. © 2018 David M. Taylor. Published 2018 by John Wiley & Sons Ltd. 0003381246.INDD 825 4/2/2018 12:35:38 PM 826 Index agitation alcohol dependence/misuse 387–404 Alzheimer’s disease (AD) 529–549 dementia see behavioural and assessment 387–388 antipsychotic‐associated pneumonia 148 psychological symptoms of brief structured intervention 387–388 atrial fibrillation and 720 dementia children and adolescents 400–401 BAP guidance 551, 551 non‐psychotropics causing 808, co‐morbid mental health cognitive enhancers 529–543, 530–531 809, 810 disorders 401–403 depression 577–578 rapid tranquillisation 54–57 concurrent drug use disorders 401 driving regulations 776 agomelatine drug interactions 753–756, 754, 755 efficacy of drug treatment 532–534 adverse effects 358 mild, assisted withdrawal 392, 393 NICE guidance 543, 544 atrial fibrillation 720 moderate, assisted withdrawal 392, non‐cognitive symptoms see behavioural breastfeeding 622 393, 393 and psychological symptoms (BPSD) cardiac effects 326 NICE guideline 387, 397, 397, 398, of dementia depression 264 399, 399 novel treatments 548–549 diabetes mellitus and 340 older adults 401 other treatments 543–548 discontinuation 310, 312, 315, 318 psychotropic drug choice 756 quantifying drug effects 534 driving ability 777 relapse prevention 397–400 stopping treatment 540–543, 543 epilepsy 692 severe, assisted withdrawal 392, 394, 394 see also dementia generalised anxiety disorder 360 treatment see alcohol withdrawal Alzheimer’s Disease Assessment hepatic impairment 639 Wernicke’s encephalopathy 395–396 Scale ‐ cognitive subscale hyperprolactinaemia and 337 alcohol intoxication (ADAS‐cog) 532, 534 hyponatraemia 333, 333 drug interactions 754, 754, 756 amantadine minimum effective dose 262 rapid tranquillisation 56 antipsychotic‐induced weight gain 100 older people 294, 295, 587 Alcohol Use Disorders Identification Test Huntington’s disease 705 overdose 769 (AUDIT) 388 hyperprolactinaemia 139 Parkinson’s disease 715 alcohol withdrawal 388–396 multiple sclerosis 711–712 renal impairment 651 carbamazepine 222 psychiatric adverse effects 810 sexual adverse effects 344 children and adolescents 400–401 refractory depression 274 smoking status and 750 clinical features 388–389 sexual dysfunction 144, 144, 345 switching to/from 316, 318 community setting 390, 393 American Academy of Child and Adolescent agranulocytosis complications 388–389 Psychiatry (AACAP) 463, 480, 491 clozapine–chemotherapy fixed dose reduction regimen 393–394 amfebutamone see bupropion combination 202 front‐loading regimen 393 amfetamines clozapine‐induced 176, 179, 184–185, inpatient/residential settings 390, 393, autism spectrum disorders 506 197–201 394–395 depression 285, 286–287 psychotropics causing 806 older adults 401 drug interactions 451–452 see also neutropenia pharmacologically assisted epilepsy 693 AIDS see HIV infection/AIDS (detoxification) 390–395, 392 misuse 439–440, 455 akathisia pregnancy 400 psychosis induced by 440 antipsychotic‐induced 39, 91–92, 94–96 somatic complaints, and remedies see also dexamfetamine; lisdexamfetamine never‐medicated schizophrenia 90 396, 396 Amiket (amitriptyline + ketamine non‐psychotropics causing 810 symptom‐triggered regimen 394, cream) 300 switching antipsychotics 150 394–395 amisulpride treatment 92, 94, 95–96 variable dose reduction 393 adverse effects 39 D‐alanine, refractory schizophrenia 163 Wernicke’s encephalopathy 395–396 alcohol misusers 756 alanine aminotransferase (ALT) 799 aldehyde dehydrogenase 753, 753 bipolar disorder 226 albumin, plasma 799 drugs inhibiting 754 breastfeeding 625 albumin:creatinine ratio (ACR) 645, 646 alfuzosin 561 clozapine‐induced hypersalivation 189 alcohol 387 alkaline phosphatase 799 delirium 674 bariatric surgery and 727 allopurinol 162, 237 dementia 572, 574, 575 driving and 777 α2‐adrenergic agonists depression 278 drug interactions 451–452, 753–757, ADHD 497 diabetes and 124–125 754, 755 autism spectrum disorders 506 epilepsy 692 metabolism 753, 753 PTSD in young people 492, 493 equivalent dose 15 methadone interaction 410, 412 tic disorders 513 hepatic impairment 637, 641 post‐mortem blood samples 742, 743 see also clonidine; guanfacine Huntington’s disease 706 units 387 alpha‐blockers maximum licensed dose 12 alcohol consumption PTSD in young people 492, 493 minimum effective dose 9 pregnancy 400 urinary retention in dementia 561, 568 monitoring physical health 37, 38 recommendations 387 alpha‐lipoic acid 100 negative symptoms 32 alcohol dehydrogenase (ADH) 753, 753 alprostadil 144, 145 older people 588 drugs inhibiting 754 alverine 563 overdose 771 0003381246.INDD 826 4/2/2018 12:35:38 PM Index 827 plasma level monitoring 732–734, 733 anticholinergic agents cross‐tapering 314 pneumonia risk 148 antidepressant discontinuation dementia 577–578 refractory schizophrenia 159, 162, symptoms 312 depression 257–359 163, 164 bronchodilators 563–564 children and adolescents relative efficacy 5 with depot antipsychotics 69 463–467, 467 renal impairment 649 extrapyramidal symptoms 92, 95 choice of agent 258 sexual adverse effects 143 hypersalivation 189, 190, 564 duration of treatment 259–260 switching to 51 Parkinson’s disease 716, 716, 717 effectiveness 257 weight gain risk 97 safety in dementia 557–564, 561, lithium augmentation 206 amitriptyline 567, 568 minimum effective doses 262, adverse effects 358 street drug interactions 452 262–263 autism spectrum disorders 508 urinary incontinence 557–561, 562, 568 next step treatments 260 breastfeeding 624 anticholinergic effect on cognition (AEC) NICE guidelines 256, 278, 307 buccal 299 scores 557, 558–560, 561 onset of action 257–258 children and adolescents 464–465 anticholinergic effects post‐stroke 290–291 clozapine‐induced hypersalivation 189 antidepressants 294–295, 296, 321, prescribing principles 255 discontinuation symptoms 311 358–359 prophylaxis 306–309 effectiveness 257 antipsychotics 39, 142 psychostimulants with 285, 286–287 gel 300, 302 anticholinesterases see acetylcholinesterase psychotic 278–279 intramuscular 302 (AChE) inhibitors refractory (resistant) 267–273, intravenous 299, 302 anticoagulation, SSRIs and 291, 268, 271 and ketamine cream 300 348–349, 350 switching 259, 264–265, 314–320, Parkinson’s disease 715 anticonvulsants 316–319 plasma level monitoring 734 alcohol dependence 389, 400 treatment algorithm 264–265 post‐mortem blood concentrations 743 autism spectrum disorders 505, 508 diabetes mellitus and 340, 340–342 post‐stroke depression 290 biochemical side‐effects 799, 802 discontinuation 312, 314–320, 316–319 PTSD 363 chronic kidney disease 647